Pich A, Chiarle R, Chiusa L, Ponti R, Geuna M, Casadio C, Maggi G, Palestro G
Department of Biomedical Sciences, University of Turin, Italy.
Am J Surg Pathol. 1995 Aug;19(8):918-26. doi: 10.1097/00000478-199508000-00007.
We performed DNA flow cytometry and analysis of the argyrophilic nucleolar organizer regions (AgNORs) in formalin-fixed, paraffin-embedded sections from 60 surgically resected thymomas. The results were correlated with histologic pattern, stage, associated clinical features, and survival to assess which parameters could best predict prognosis. On univariate analysis, the 10-year survival rates were 86% for predominantly lymphocytic type but only 42% for predominantly epithelial, mixed lymphoepithelial, or spindle cell thymomas (p = 0.006); survival rates were 85% for noninvasive but only 34% for invasive thymomas (p = 0.0002); 73% for diploid but only 38% for aneuploid cases (p = 0.005); 88% for thymomas with 5.75 AgNORs per cell or fewer but only 34% for thymomas with more than 5.75 AgNORs per cell (p < 0.0001). On multivariate survival analysis, tumor stage (p < 0.001) and AgNOR counts (p = 0.009) retained independent prognostic significance. The 16 patients with predominantly lymphocytic type and 5.75 AgNORs per cell or fewer were all alive at the end of the observation period. In conclusion, the histologic type of the American classification and the proliferative activity evaluated by AgNOR analysis are the best predictors of long-term survival for patients with thymoma. Both predictors can be easily evaluated in the same histologic section, are highly reproducible, and permit identification of a group of patients with a favorable outcome regardless of other clinicopathological features.
我们对60例手术切除的胸腺瘤经福尔马林固定、石蜡包埋的切片进行了DNA流式细胞术及嗜银核仁组织区(AgNORs)分析。将结果与组织学类型、分期、相关临床特征及生存率进行关联分析,以评估哪些参数能最佳预测预后。单因素分析显示,主要为淋巴细胞型胸腺瘤的10年生存率为86%,而主要为上皮型、混合淋巴细胞上皮型或梭形细胞胸腺瘤的10年生存率仅为42%(p = 0.006);非侵袭性胸腺瘤的生存率为85%,而侵袭性胸腺瘤的生存率仅为34%(p = 0.0002);二倍体病例的生存率为73%,而非整倍体病例的生存率仅为38%(p = 0.005);每个细胞AgNORs数量为5.75个或更少的胸腺瘤的生存率为88%,而每个细胞AgNORs数量超过5.75个的胸腺瘤的生存率仅为34%(p < 0.0001)。多因素生存分析显示,肿瘤分期(p < 0.001)和AgNOR计数(p = 0.009)保留独立的预后意义。16例主要为淋巴细胞型且每个细胞AgNORs数量为5.75个或更少的患者在观察期末均存活。总之,美国分类法的组织学类型以及通过AgNOR分析评估的增殖活性是胸腺瘤患者长期生存的最佳预测指标。这两个预测指标均可在同一组织学切片中轻松评估,具有高度可重复性,并且无论其他临床病理特征如何,均可识别出一组预后良好的患者。